Chemistry: molecular biology and microbiology – Micro-organism – tissue cell culture or enzyme using process... – Recombinant dna technique included in method of making a...
Reexamination Certificate
1998-09-15
2001-12-18
Allen, Marianne P. (Department: 1645)
Chemistry: molecular biology and microbiology
Micro-organism, tissue cell culture or enzyme using process...
Recombinant dna technique included in method of making a...
C435S006120, C435S320100, C435S325000, C435S253400, C435S069700, C536S023100, C536S023700
Reexamination Certificate
active
06331411
ABSTRACT:
FIELD OF THE INVENTION
This invention relates to newly identified polynucleotides and polypeptides, and their production and uses, as well as their variants, agonists and antagonists, and their uses. In particular, the invention relates to polynucleotides and polypeptides of the topomerase 1 family, as well as their variants, hereinafter referred to as “topA,” “topA polynucleotide(s),” and “topA polypeptide(s)” as the case may be.
BACKGROUND OF THE INVENTION
The Streptococci make up a medically important genera of microbes known to cause several types of disease in humans, including, for example, otitis media, conjunctivitis, pneumonia, bacteremia, meningitis, sinusitis, pleural empyema and endocarditis, and most particularly meningitis, such as for example infection of cerebrospinal fluid. Since its isolation more than 100 years ago, Streptococcus pneumoniae has been one of the more intensively studied microbes. For example, much of our early understanding that DNA is, in fact, the genetic material was predicated on the work of Griffith and of Avery, Macleod and McCarty using this microbe. Despite the vast amount of research with
S. pneumoniae
, many questions concerning the virulence of this microbe remain. It is particularly preferred to employ Streptococcal genes and gene products as targets for the development of antibiotics.
The frequency of
Streptococcs pneumoniae
infections has risen dramatically in the past few decades. This has been attributed to the emergence of multiply antibiotic resistant strains and an increasing population of people with weakened immune systems. It is no longer uncommon to isolate
Streptococcus pneumoniae
strains which are resistant to some or all of the standard antibiotics. This phenomenon has created an unmet medical need and demand for new anti-microbial agents, vaccines, drug screening methods, and diagnostic tests for this organism.
Moreover, the drug discovery process is currently undergoing a fundamental revolution as it embraces “functional genomics,” that is, high throughput genome- or gene-based biology. This approach is rapidly superseding earlier approaches based on “positional cloning” and other methods. Functional genomics relies heavily on the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available as well as from other sources. There is a continuing and significant need to identify and characterize further genes and other polynucleotides sequences and their related polypeptides, as targets for drug discovery.
Clearly, there exists a need for polynucleotides and polypeptides, such as the topA embodiments of the invention, that have a present benefit of, among other things, being useful to screen compounds for antimicrobial activity. Such factors are also useful to determine their role in pathogenesis of infection, dysfunction and disease. There is also a need for identification and characterization of such factors and their antagonists and agonists to find ways to prevent, ameliorate or correct such infection, dysfunction and disease.
SUMMARY OF THE INVENTION
The present invention relates to topA, in particular topA polypeptides and topA polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including treatment of microbial diseases, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists using the materials provided by the invention, and for treating microbial infections and conditions associated with such infections with the identified agonist or antagonist compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with microbial infections and conditions associated with such infections, such as assays for detecting topA expression or activity.
Various changes and modifications within the spirit and scope of the disclosed invention will become readily apparent to those skilled in the art from reading the following descriptions and from reading the other parts of the present disclosure.
DESCRIPTION OF THE INVENTION
The invention relates to topA polypeptides and polynucleotides as described in greater detail below. In particular, the invention relates to polypeptides and polynucleotides of a topA of
Streptococcus pneumoniae,
which is related by amino acid sequence homology to top1 polypeptide. The invention relates especially to topA having the nucleotide and amino acid sequences set out in Table 1 as SEQ ID NO:1 or 3 and SEQ ID NO:2 or 4 respectively. Note that sequences recited in the Sequence Listing below as “DNA” represent an exemplification of the invention, since those of ordinary skill will recognize that such sequences can be usefully employed in polynucleotides in general, including ribopolynucleotides.
TABLE 1
topA Polynucleotide and Polypeptide Sequences
(A)
Streptococcus pneumoniae
topA polynucleotide sequence [SEQ ID NO:1].
5′-
AAAACTTTTCTTCTATTATAGTAGCTAAGTCTTGACAGGGTTCAAAAATGGTTTACACTTTATAAAGTTTA
TTACTTTG
AAAAGGTGTGATACTGTGGCTACGGCAACAAAAAAGACAAAATCAACAGTTAAAAAAAATCTAGTCATCGTG
GAGTCGCC
TGCTAAGGCCAAGACGATTGAAAAATATCTAGGCAGAAACTACAAGGTTTTAGCCAGTGTCGGGCATATCCG
TGATTTGA
AGAAATCCAGTATGTCCGTCGATATTGAAAATAATTATGAACCGCAATATATCAATATCCGAGGAAAAGGCC
CTCTTATC
AATGACTTGAAAAAAGAAGCTAAAAAAGCTAATAAAGTTTTTCTCGCGAGTGACCCGGACCGTGAAGGAGAA
GCGATTTC
TTGGCATTTGGCCCATATTCTCAACTTGGATGAAAATGATGCCAACCGTGTGGTCTTCAATGAAATCACCAA
GGATGCAG
TCAAAAATGCTTTTAAAGAACCTCGTAAGATCGATATGGACTTGGTCGATGCCCAACAAGCTCGTCGGATCT
TGGATCGC
TTGGTAGGGTATTCGATTTCGCCTATTTTGTGGAAGAAGGTCAAGAAGGGCTTGTCAGCAGGTCGCGTTCAG
TCCATTGC
CCTTAAACTCATCATTGACCGTGAAAATGAAATCAATGCCTTCCAGCCAGAAGAATACTGGACAGTTGATGC
TGTCTTTA
AAAAGGGAACCAAACAATTTCATGCTTCCTTCTATGGAGTAGATGGTAAAAAGATGAAACTGACCAGCAATG
ACGAAGTC
AAGGAAGTCTTGTCTCGTCTGACGAGTAAAGACTTTTCAGTAGATCAGGTGGATAAGAAAGAGCGCAAGCGC
AATGCTCC
TTTACCCTATACCACTTCATCTATGCAGATGGATGCTGCCAATAAAATCAATTTCCGTACTCGAAAAACCAT
GATGGTTG
CCCAACAGCTCTATGAAGGAATTAATATCGGTACTGGTGTTCAAGGTTTGATTACCTATATGCGTACCGATT
CGACTCGT
ATCAGTCCTGTAGCGCAAAATGAGGCGGCAAGCTCCATTACGGATCGTTTTGGTAGTAAGTATACTAAACAC
GGTAGCAA
GGTCAAAAACGCATCAGGTGCTCAGGATGCCCATGAGGCTATTCGTCCGTCAAGTGTCTTTAATACACCAAA
AAGCATCG
CTAATTATCTGGACAAGGATCAGCTCAACCTATATACCCTTATCTGGAATCGTTTTGTGGCTAGCCATATGA
CAGCGGCC
GTTTTTGATACCATGGCTGTTAAATTGTCTCAAAAAGGGGTTCAATTTGCTGCCAATGGTAGTCAGGTTAAG
TTTGATGG
TTATCTTACCATTTATAATGATTCTGACAAGAATAAGATGTTACCGGACATGGTTGTTGGAGATGTGGTCAA
ACAGGTCA
ATAGCAAACCAGAGCAACATTTCACCCAACCGCCTGCCCGTTATTCTGAAGCAACACTGATTAAAACCTTAG
AGGAAAAT
GGGGTTGGACGTCCATCAACCTACGCGCCAACCATTGAAACCATTCAGAAACGTTATTATGTTCGCCTGGCA
GCCAAACG
TTTTGAACCGACAGAGTTGGGAGAAATTGTCAATAAGCTCATCGTTGAATATTTCCCAGATATCGTAAACGT
GACCTTCA
CAGCTGAAATGGAAGGTAAACTGGATGATGTCGAAGTTGGAAAAGAGCAGTGGCGACGGGTCATTGATGCCT
TTTACAAA
CCATTCTCTAAAGAAGTTGCCAAGGCTGAAGAAGAAATGGAAAAAATCCAGATTAAGGATGAACCAGCTGGA
TTTGACTG
TGAAGTGTGTGGCAGTCCAATGGTCATTAAACTTGGTCGTTTTGGTAAATTCTACGCTTGTAGCAATTTCCC
AGATTGCC
GTCATACCCAAGCAATCGTGAAAGAGATTGGTGTTGAGTGTCCAAGCTGTCATCAGGGACAAATTATTGAGC
GAAAAACC
AAGCGTAATCGCCTATTCTATGGTTGCAATCGCTATCCAGAATGTGAATTTACCTCTTGGGACAAGCCTGTT
GGTCGTGA
CTGTCCAAAATGTGGCAACTTCCTCATGGAGAAAAAAGTCCGTGGTGGTGGCAAGCAGGTTGTTTGTAGCAA
AGGCGACT
ACGAGGAAGAAAAGATTAAATAA- 3′
(B)
Streptococcus pneumoniae
topA polypeptide sequence deduced from a
polynucleotide sequence in this table [SEQ ID NO:2]
.
NH
2
-
VATATKKTKSTVKKNLVIVESPAKAKTIEKYLGRNYKVLASVGHIRDLKKSSMSVDIENNYEPQYINIRGKG
PLINDLKK
EAKKANKVFLASDPDREGEAISWHLAHILNLDENDANRVVFNEITKDAVKNAFKEPRKIDMDLVDAQQARRI
LDRLVGYS
ISPILWKKVKKGLSAGRVQSIALKLIIDRENEINAFQPEEYWTVDAVFKKGTKQFHASFYGVDGKKMKLTSN
DEVKEVLS
RLTSKDFSVDQVDKKERKRNAPLPYTTSSMQMDAANKINFRTRKTMMVAQQLYEGINIGTGVQGLITYMRTD
STRISPVA
QNEAASSITDRFGSKYTKHGSKVKNASGAQDAHEAIRPSSVFNTPKSIANYLDKDQLNLYTLIWNRFVASHM
TAAVFDTM
AVKLSQKGVQFAANGSQVKFDGYLTIYNDSDKNKMLPDMVVGDVVKQVNSKPEQHFTQPPARYSEATLIKTL
EENGVGRP
STYAPTIETIQKRYYVRLAAKRFEPTELGEIVNKLIVEYFPDIVNVTFTAEMEGKLDDVEVG
Gwynn Michael
Kallender Howard
Katz Lisa K
Sylvester Daniel
Traini Christopher M
Allen Marianne P.
Deibert Thomas S.
Gimmi Edward R.
King William T.
SmithKline Beecham Corporation
LandOfFree
TopA does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with TopA, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and TopA will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2585622